These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

176 related items for PubMed ID: 38439606

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Tafamidis Efficacy Among Octogenarian Patients in the Phase 3 ATTR-ACT and Ongoing Long-Term Extension Study.
    Garcia-Pavia P, Sultan MB, Gundapaneni B, Sekijima Y, Perfetto F, Hanna M, Witteles R.
    JACC Heart Fail; 2024 Jan; 12(1):150-160. PubMed ID: 37943223
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study.
    Damy T, Garcia-Pavia P, Hanna M, Judge DP, Merlini G, Gundapaneni B, Patterson TA, Riley S, Schwartz JH, Sultan MB, Witteles R.
    Eur J Heart Fail; 2021 Feb; 23(2):277-285. PubMed ID: 33070419
    [Abstract] [Full Text] [Related]

  • 7. Causes of Cardiovascular Hospitalization and Death in Patients With Transthyretin Amyloid Cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial [ATTR-ACT]).
    Miller AB, Januzzi JL, O'Neill BJ, Gundapaneni B, Patterson TA, Sultan MB, López-Sendón J.
    Am J Cardiol; 2021 Jun 01; 148():146-150. PubMed ID: 33667442
    [Abstract] [Full Text] [Related]

  • 8. Efficacy of Tafamidis in Patients With Hereditary and Wild-Type Transthyretin Amyloid Cardiomyopathy: Further Analyses From ATTR-ACT.
    Rapezzi C, Elliott P, Damy T, Nativi-Nicolau J, Berk JL, Velazquez EJ, Boman K, Gundapaneni B, Patterson TA, Schwartz JH, Sultan MB, Maurer MS.
    JACC Heart Fail; 2021 Feb 01; 9(2):115-123. PubMed ID: 33309574
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathy.
    Kazi DS, Bellows BK, Baron SJ, Shen C, Cohen DJ, Spertus JA, Yeh RW, Arnold SV, Sperry BW, Maurer MS, Shah SJ.
    Circulation; 2020 Apr 14; 141(15):1214-1224. PubMed ID: 32078382
    [Abstract] [Full Text] [Related]

  • 11. Health impact of tafamidis in transthyretin amyloid cardiomyopathy patients: an analysis from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and the open-label long-term extension studies.
    Rozenbaum MH, Garcia A, Grima D, Tran D, Bhambri R, Stewart M, Li B, Heeg B, Postma M, Masri A.
    Eur Heart J Qual Care Clin Outcomes; 2022 Aug 17; 8(5):529-538. PubMed ID: 33895806
    [Abstract] [Full Text] [Related]

  • 12. Improved long-term survival with tafamidis treatment in patients with transthyretin amyloid cardiomyopathy and severe heart failure symptoms.
    Elliott P, Gundapaneni B, Sultan MB, Ines M, Garcia-Pavia P.
    Eur J Heart Fail; 2023 Nov 17; 25(11):2060-2064. PubMed ID: 37434378
    [Abstract] [Full Text] [Related]

  • 13. Tafamidis and quality of life in people with transthyretin amyloid cardiomyopathy in the study ATTR-ACT: A plain language summary.
    Hanna M, Damy T, Grogan M, Stewart M, Gundapaneni B, Sultan MB, Maurer MS.
    Future Cardiol; 2022 Mar 17; 18(3):165-172. PubMed ID: 34779246
    [Abstract] [Full Text] [Related]

  • 14. Association of Tafamidis With Health Status in Patients With ATTR Cardiac Amyloidosis: A Post Hoc Analysis of the ATTR-ACT Randomized Clinical Trial.
    Sperry BW, Hanna M, Maurer MS, Nativi-Nicolau J, Floden L, Stewart M, Wyrwich KW, Barsdorf AI, Kapadia H, Spertus JA.
    JAMA Cardiol; 2023 Mar 01; 8(3):275-280. PubMed ID: 36723935
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Tafamidis: A First-in-Class Transthyretin Stabilizer for Transthyretin Amyloid Cardiomyopathy.
    Park J, Egolum U, Parker S, Andrews E, Ombengi D, Ling H.
    Ann Pharmacother; 2020 May 01; 54(5):470-477. PubMed ID: 31735059
    [Abstract] [Full Text] [Related]

  • 19. Tafamidis: A Review in Transthyretin Amyloid Cardiomyopathy.
    Lamb YN.
    Am J Cardiovasc Drugs; 2021 Jan 01; 21(1):113-121. PubMed ID: 33469827
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.